Browsing by Author "Yogesh K. Chawla"

Now showing 1 - 6 of 6

2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations
(Elsevier B.V., 2020) Ashish Kumar; Subrat K. Acharya; Shivaram P. Singh; Anil Arora; Radha K. Dhiman; Rakesh Aggarwal; Anil C. Anand; Prashant Bhangui; Yogesh K. Chawla; Siddhartha Datta Gupta; Vinod K. Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S. Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V.G. Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B. Paul; Padaki N. Rao; Mohamed Rela; Manoj K. Sahu; Vivek A. Saraswat; Samir R. Shah; Shalimar; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations. © 2019
Erratum: Corrigendum to “Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: Update 2016” (Journal of Clinical and Experimental Hepatology (2016) 6(2) (119–145) (S0973688316302584) (10.1016/j.jceh.2016.07.001))
(Elsevier B.V., 2016) Pankaj Puri; Vivek A. Saraswat; Radha K. Dhiman; Anil C. Anand; Subrat K. Acharya; Shivaram P. Singh; Yogesh K. Chawla; Deepak N. Amarapurkar; Ajay Kumar; Anil Arora; Vinod K. Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Shalimar; Gaurav Pandey; Rohan Malik; Swastik Agrawal
The authors regret for the typological error in Table 3 published in the original version of the article. The corrected version of Table 3 is given below: The authors would like to apologise for any inconvenience caused. © 2016
INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease
(Elsevier B.V., 2021) Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K. Acharya; Sanjay K. Agarwal; Rakesh Aggarwal; Anil C. Anand; Anil K. Bhalla; Narendra S. Choudhary; Yogesh K. Chawla; Radha K. Dhiman; Vinod K. Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N. Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P. Mathur; Suman L. Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R. Rai; Sree B. Raju; Devinder S. Rana; Padaki N. Rao; Manish Rathi; Vivek A. Saraswat; Sanjiv Saxena; Shalimar; Praveen Sharma; Shivaram P. Singh; Ashwani K. Singal; Arvinder S. Soin; Sunil Taneja; Santosh Varughese
Renal dysfunction is very common among patients with chronic liver disease, and concomitant liver disease can occur among patients with chronic kidney disease. The spectrum of clinical presentation and underlying etiology is wide when concomitant kidney and liver disease occur in the same patient. Management of these patients with dual onslaught is challenging and requires a team approach of hepatologists and nephrologists. No recent guidelines exist on algorithmic approach toward diagnosis and management of these challenging patients. The Indian National Association for Study of Liver (INASL) in association with Indian Society of Nephrology (ISN) endeavored to develop joint guidelines on diagnosis and management of patients who have simultaneous liver and kidney disease. For generating these guidelines, an INASL-ISN Taskforce was constituted, which had members from both the societies. The taskforce first identified contentious issues on various aspects of simultaneous liver and kidney diseases, which were allotted to individual members of the taskforce who reviewed them in detail. A round-table meeting of the Taskforce was held on 20–21 October 2018 at New Delhi to discuss, debate, and finalize the consensus statements. The evidence and recommendations in these guidelines have been graded according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) system with minor modifications. The strength of recommendations (strong and weak) thus reflects the quality (grade) of underlying evidence (I, II, III). We present here the INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. © 2020 Indian National Association for Study of the Liver
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015
(Elsevier B.V., 2015) Pankaj Puri; Anil C. Anand; Vivek A. Saraswat; Subrat K. Acharya; Radha K. Dhiman; Shiv K. Sarin; Shivaram P. Singh; Yogesh K. Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K. Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Shalimar; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S. Puri; C.E. Eapen; Sandeep Thareja
Overall prevalence of HCV infection in India has been estimated to be approximately 1.3% in the general population. Recent introduction of sofosbuvir in India at a relatively affordable price has led to great optimism about prospects of cure for these patients. This drug is likely to form the backbone of current and future treatment regimes for HCV infection, displacing pegylated interferon. Availability of directly acting antiviral drugs (DAAs) has necessitated revision of INASL guidelines for the treatment of HCV published in 2014, as has happened across the world. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. Since only one DAA, sofosbuvir, is available in India, only two sofosbuvir-based regimes are possible: either dual drug therapy in combination with ribavirin alone for 6 months or triple drug therapy in combination with ribavirin and pegylated interferon for 3 months. The utility of these regimes in various situations has been discussed. Availability of a few other newer DAAs, expected in 2016, is expected to lead to more widespread use of these agents. Current guidance will be updated once newer DAAs, newer evidence with DAAs and 'real-life experience' with use of DAAs accumulate in India. © 2015 INASL.
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016
(Elsevier B.V., 2016) Pankaj Puri; Vivek A. Saraswat; Radha K. Dhiman; Anil C. Anand; Subrat K. Acharya; Shivaram P. Singh; Yogesh K. Chawla; Deepak N. Amarapurkar; Ajay Kumar; Anil Arora; Vinod K. Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Shalimar; Gaurav Pandey; Rohan Malik; Swastik Agrawal
India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. © 2016 INASL
Indian National Association for the Study of the Liver—Federation of Obstetric and Gynaecological Societies of India Position Statement on Management of Liver Diseases in Pregnancy
(Elsevier B.V., 2019) Anil Arora; Ashish Kumar; Anil C. Anand; Pankaj Puri; Radha K. Dhiman; Subrat K. Acharya; K. Aggarwal; Neelam Aggarwal; Rakesh Aggarwal; Yogesh K. Chawla; Vinod K. Dixit; Ajay Duseja; Chundamannil E. Eapen; Bhabadev Goswami; Kanwal Gujral; A. Gupta; A. Jindal; Premashish Kar; Krishna Kumari; Kaushal Madan; Jaideep Malhotra; Narendra Malhotra; Gaurav Pandey; Uma Pandey; Ratna D. Puri; Ramesh R. Rai; Padaki N. Rao; Shiv K. Sarin; Aparna Sharma; Praveen Sharma; Koticherry T. Shenoy; Karam R. Singh; Shivaram P. Singh; Vanita Suri; Nirupama Trehanpati; M. Wadhawan
Liver diseases occurring during pregnancy can be serious and can progress rapidly, affecting outcomes for both the mother and fetus. They are a common cause of concern to an obstetrician and an important reason for referral to a hepatologist, gastroenterologist, or physician. Liver diseases during pregnancy can be divided into disorders unique to pregnancy, those coincidental with pregnancy, and preexisting liver diseases exacerbated by pregnancy. A rapid differential diagnosis between liver diseases related or unrelated to pregnancy is required so that specialist and urgent management of these conditions can be carried out. Specific Indian guidelines for the management of these patients are lacking. The Indian National Association for the Study of the Liver (INASL) in association with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) had set up a taskforce for development of consensus guidelines for management of patients with liver diseases during pregnancy, relevant to India. For development of these guidelines, a two-day roundtable meeting was held on 26–27 May 2018 in New Delhi, to discuss, debate, and finalize the consensus statements. Only those statements that were unanimously approved by most members of the taskforce were accepted. The primary objective of this review is to present the consensus statements approved jointly by the INASL and FOGSI for diagnosing and managing pregnant women with liver diseases. This article provides an overview of liver diseases occurring in pregnancy, an update on the key mechanisms involved in its pathogenesis, and the recommended treatment options. © 2019